Published in:
Open Access 01-12-2019 | Erythropoietin | Research article
Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study
Published in: BMC Nephrology | Issue 1/2019
Login to get accessAbstract
Background
DOPPS reported that thousands of life-years could be gained in the US and Europe over 5 years by correcting six modifiable haemodialysis practices. We estimated potential life-years gained across 10 European countries using MONITOR-CKD5 study data.
Methods
The DOPPS-based target ranges were used, except for haemoglobin due to label changes, as well as DOPPS-derived relative mortality risks. Percentages of MONITOR-CKD5 patients outside targets were calculated. Consistent with the DOPPS-based analyses, we extrapolated life-years gained for the MONITOR-CKD5 population over 5 years if all patients were within targets.
Results
Bringing the 10 MONITOR-CKD5 countries’ dialysis populations into compliance on the six practices results in a 5-year gain of 97,428 patient-years. In descending order, survival impact was the highest for albumin levels, followed by phosphate levels, vascular access, haemoglobin, dialysis adequacy, and interdialytic weight gain.
Conclusions
Optimal management of the six modifiable haemodialysis practices may achieve 6.2% increase in 5-year survival.
Trial Registration
NCT01121237. Clinicaltrials.gov registration May 12, 2010 (retrospectively registered).